These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20573084)

  • 41. A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity.
    Moreau P; Kergueris MF; Milpied N; Le Tortorec S; Mahé B; Bulabois CE; Rapp MJ; Larousse C; Bataille R; Harousseau JL
    Br J Haematol; 1996 Dec; 95(3):527-30. PubMed ID: 8943896
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders.
    Chandra S; Mizuno K; Zhao J; Davies SM; Marsh RA; Fukuda T; Setchell KDR; Vinks AA; Mehta PA
    Br J Clin Pharmacol; 2022 Jan; 88(1):115-127. PubMed ID: 34075614
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial.
    Sonneveld P; van der Holt B; Segeren CM; Vellenga E; Croockewit AJ; Verhoe GE; Cornelissen JJ; Schaafsma MR; van Oers MH; Wijermans PW; Westveer PH; Lokhorst HM;
    Haematologica; 2007 Jul; 92(7):928-35. PubMed ID: 17606443
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation.
    Nath CE; Shaw PJ; Montgomery K; Earl JW
    Br J Clin Pharmacol; 2005 Mar; 59(3):314-24. PubMed ID: 15752378
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma.
    Nath CE; Grigg A; Rosser SPA; Estell J; Newman E; Tiley C; Ramanathan S; Ho SJ; Larsen S; Gibson J; Presgrave P; Shaw PJ; Trotman J
    Eur J Clin Pharmacol; 2022 Dec; 78(12):1911-1921. PubMed ID: 36205743
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.
    Bashir Q; Thall PF; Milton DR; Fox PS; Kawedia JD; Kebriaei P; Shah N; Patel K; Andersson BS; Nieto YL; Valdez BC; Parmar S; Rondon G; Delgado R; Hosing C; Popat UR; Oran B; Ciurea SO; Lin P; Weber DM; Thomas SK; Lee HC; Manasanch EE; Orlowski RZ; Williams LA; Champlin RE; Qazilbash MH
    Lancet Haematol; 2019 May; 6(5):e266-e275. PubMed ID: 30910541
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
    Blanes M; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Bladé J; San Miguel JF; Sanz MA; de la Rubia J
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.
    Lahuerta JJ; Mateos MV; Martínez-López J; Grande C; de la Rubia J; Rosiñol L; Sureda A; García-Laraña J; Díaz-Mediavilla J; Hernández-García MT; Carrera D; Besalduch J; de Arriba F; Oriol A; Escoda L; García-Frade J; Rivas-González C; Alegre A; Bladé J; San Miguel JF;
    Haematologica; 2010 Nov; 95(11):1913-20. PubMed ID: 20663944
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.
    Batlle M; Morgades M; Vives S; Ferrà C; Oriol A; Sancho JM; Xicoy B; Moreno M; Magallón L; Ribera JM
    Eur J Haematol; 2014 Dec; 93(6):487-91. PubMed ID: 24889275
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
    Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M
    Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.
    Palumbo A; Bringhen S; Bruno B; Falcone AP; Liberati AM; Grasso M; Ria R; Pisani F; Cangialosi C; Caravita T; Levi A; Meloni G; Nozza A; Pregno P; Gabbas A; Callea V; Rizzo M; Annino L; De Stefano V; Musto P; Baldi I; Cavallo F; Petrucci MT; Massaia M; Boccadoro M
    Blood; 2010 Mar; 115(10):1873-9. PubMed ID: 19965659
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
    Dispenzieri A; Wiseman GA; Lacy MQ; Litzow MR; Anderson PM; Gastineau DA; Tefferi A; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Lust JA; Greipp PR; Rajkumar SV; Fonseca R; Witzig TE; Erlichman C; Sloan JA; Gertz MA
    Leukemia; 2005 Jan; 19(1):118-25. PubMed ID: 15526021
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma.
    Barta SK; Jain R; Mazumder A; Carter J; Almanzar L; Browne R; Shahnaz S; Elkind R; Kaminetzky D; Battini R; Derman O; Kornblum N; Verma A; Braunschweig I
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):650-657. PubMed ID: 28684379
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma.
    Sirohi B; Powles R; Kulkarni S; Rudin C; Saso R; Rigg A; Horton C; Singhal S; Mehta J; Treleaven J
    Br J Cancer; 2001 Aug; 85(3):325-32. PubMed ID: 11487259
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Severe gastrointestinal mucositis following high dose melphalan therapy for multiple myeloma.
    Sharma SK; Handoo A; Choudhary D; Dhamija G; Gupta N
    World J Gastroenterol; 2013 Feb; 19(5):784-5. PubMed ID: 23429569
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients.
    Osterborg A; Ehrsson H; Eksborg S; Wallin I; Mellstedt H
    Eur J Cancer Clin Oncol; 1989 May; 25(5):899-903. PubMed ID: 2737222
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
    Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
    J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term outcomes of innovator versus generic melphalan formulation in autologous hematopoietic cell transplantation for multiple myeloma.
    Lad DP; Malhotra P; Patil AN; Nampoothiri RV; Kasudhan KS; Khadwal A; Prakash G; Jain A; Malhotra S; Varma N; Attri SV; Varma S
    Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):114-118. PubMed ID: 32622756
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma.
    Qazilbash MH; Saliba RM; Hosing C; Mendoza F; Qureshi SR; Weber DM; Wang M; Flosser T; Couriel DR; De Lima M; Kebriaei P; Popat U; Alousi AM; Champlin RE; Giralt SA
    Bone Marrow Transplant; 2007 Mar; 39(5):279-83. PubMed ID: 17262062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.